ZYXEL
27.2.2024 16:55:34 CET | Business Wire | Press release
Türk Telekom, pioneer of digital transformation Türkiye, has completed the world’s first mass deployment of Software-Defined Fiber Broadband. By using Netsia’s BB Suite and Zyxel’s Whitebox OLT, Türk Telekom has taken an important step towards fulfilling its virtualized and disaggregated broadband network strategy and thus, providing world-class, modern, high quality and high-speed broadband services.
“Beyond our role as a telecommunications operator, we are leading Türkiye's ambition to become a significant player in technology exports through our pioneering initiatives and partnerships. While supporting our local ecosystem through collaborations within our country, we are also elevating the prestige and value of our nation through our global endeavors," says Ümit Önal, CEO at Türk Telekom. “The cutting-edge fiber infrastructure technology product Zyxel, developed by Argela, our company renowned for innovative solutions, along with its US subsidiary Netsia, has evolved into an innovation that sets global standards. We are delighted to contribute to our country's vision of becoming a technology-exporting nation through the contract we have signed with Zyxel.”
Zyxel and Netsia have successfully completed the integration of Zyxel’s SDA Series Combo Whitebox OLT with Netsia’s BB Suite to realize the fully disaggregated broadband access network. The integrated solution has been tested in Türk Telekom’s live network and is now ready for deployment by all service providers globally. The partnership was made official with a contract signing ceremony held at this year’s Mobile World Congress on February 27. In attendance for the signing ceremony was Republic of Türkiye Deputy Transport and Infrastructure Minister Ömer Fatih Sayan.
The Netsia BB Suite provides network operators with an open, multi-vendor platform based on open-source SEBA project and BBF data models. Netsia BB Suite enables network operators to extend software defined programming to the fixed access network with customized support for each operator’s unique services and workflows. By enabling a fully disaggregated network, service providers are no longer committed to one vendor to fulfill all their needs. Instead, they have full flexibility to choose products and partners that work best for them, while having the flexibility to customize the solution to their needs.
Türk Telekom chose Zyxel’s Multi SDA products , which are all-in-one PON Whitebox OLT’s that are fully equipped to provide scalability, flexibility and interoperability to the Netsia BB Suite. The OLT’s have features that simultaneously support XGS-PON, GPON and Combo PON technologies, designed to make it easier for operators to adopt new technologies that integrate seamlessly with this solution.
“Netsia’s BB Suite is one of the most mature versatile solutions in the market, and our SDA Series Combo is designed to jointly further the network disaggregation evolution,” says Karsten Gewecke, President at Zyxel Communications. “We wanted to develop a flexible, future proof solution that creates an open broadband-access environment with vendor-agnostic hardware, keeping service providers ahead of the competition.”
Netsia CEO C. Bora Eliaçık says: “Türk Telekom, a globally recognized leader in telecommunications, is at the forefront of innovation in the Software-defined Fiber Broadband arena. We are honored to partner with them on this transformative journey. Our Netsia BB Suite product is designed to revolutionize how operators manage their access networks by providing a unified, powerful management solution. This collaboration marks a significant milestone in the evolution of access network management.” Eliaçık adds: “Our BB Suite allows the broadband access network to adapt itself to different service requirements and customer experience needs. The solution also supports the operators to optimize the CAPEX and OPEX costs by breaking the vendor lock, allowing more controllable and flexible PON networks and thus enabling critical features and services in the network. Our cooperation with Zyxel is extremely fruitful and we thank them for their collaboration and look forward to continuing our successful partnership.”
About Türk Telekom:
Türk Telekom, with over 180 years of history, is the first integrated telecommunications operator in Türkiye. Having a wide service network and product range in the fields of individual and corporate services, Türk Telekom unified its mobile, internet, phone and TV products and services under the single “Türk Telekom” brand. “Türkiye’s Multiplay Provider” Türk Telekom has 17.4 million fixed access lines, 15.1 million fixed broadband, 26.1 million mobile and 2.9 million TV subscribers as of September 30, 2023. Türk Telekom Group Companies provide services in all 81 cities of Türkiye with nearly 38.000 employees with the vision of introducing new technologies to Türkiye and accelerating Türkiye’s transformation into an information society. www.turktelekom.com.tr
About Netsia:
Netsia, a US subsidiary of Argela, is based in Santa Clara, California in the heart of Silicon Valley. With key architects, engineers and product people, Netsia is developing leading edge solutions for the telecom industry. Netsia is in active participation with open source communities and standards bodies and provides enriched, telco-grade, and supported distributions of the open source platforms. www.netsia.com
About Zyxel Communications
Zyxel Communications delivers technological innovations and has connected the world to the internet for more than 30 years. Whether establishing access through fixed or mobile broadband solutions, Zyxel Communications offers a comprehensive and flexible portfolio of products that’s keeping service providers ahead of the competition. Come by our booth at MWC 2024 to know more about our solutions and partnerships: Homepage | EMEA | Zyxel
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227158748/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom